Article · Volume 5, Issue 3 · pp. 222–224
Delamanid: A new armor in combating drug‑resistant tuberculosis
Alphienes Stanley Xavier1, Mageshwaran Lakshmanan1
- 1Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.
Abstract
Intense search has been made in the discovery of newer anti‑TB drugs to tackle the issues such as drug resistance, HIV co‑infection and risk of drug‑drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR‑TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug‑drug interactions and better tolerability.
Keywords: Delamanid; multidrug‑resistant tuberculosis; mycolic acid inhibitor
The full text of this article is available as a PDF. Open the PDF.